Company
Melodia Therapeutics, Basel
Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Also known as Melodia Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Basel, Switzerland
Claim, correct or request removal
Record updated 28 September 2026
About
We focus on respiratory, dermatologic, and systemic inflammatory disorders where current treatments are inadequate, and aim to become a leader in anti-granulocyte therapies.
Loading relationship preview